open access

Vol 11, No 6 (2007)
Prace oryginalne
Published online: 2007-10-09
Get Citation

The I/D ACE gene polymorphism and antihypertensive efficacy of losartan in patients with primary hypertension

Magdalena Makowiecka-Cieśla, Andrzej Januszewicz, Grażyna Adler, Agnieszka Bińczak-Kuleta, Iwona Gorący, Mariusz Kaczmarczyk, Jadwiga Janas, Aleksander Prejbisz, Agata Kubaszek, Andrzej Ciechanowicz
Nadciśnienie tętnicze 2007;11(6):498-504.

open access

Vol 11, No 6 (2007)
Prace oryginalne
Published online: 2007-10-09

Abstract

Background The insertion/deletion (I/D) ACE gene polymorphism seems the most widely studied sequence variant of human genome. Although evidence implicates the linkage of ACE locus and the risk for arterial hypertension, there are confounding data regarding association of ACE gene polymorphism with blood pressure (BP) response to antihypertensive therapy in patients with essential hypertension.
Therefore the aim of our study was to evaluate the association between I/D ACE polymorphism and antihypertensive efficacy of an angiotensin II receptor blocker - losartan.
Material and methods Fifty patients (mean age 47 ± 8 years) with essential hypertension (stage I-II , ESH/ESC, 2007) were included into the study. The patients were treated with losartan starting from dose of 50 mg once daily. The dose could be increased up to 100 mg once daily if there was no normalization of blood pressure after 4 weeks of treatment. The ambulatory BP measurements (ABPM), clinic BP measurements as well as evaluation of plasma renin activity and serum angiotensin II concentration measurements were performed before and after 8 weeks of treatment. The ACE genotypes were identified by PCR method.
Results The frequency distribution of ACE genotypes were as follows: 20% II homozygotes, 50% ID heterozygotes and 30% DD homozygotes. There were no significant differences in clinic characteristics and baseline BP levels among II, ID or DD patients. After 8 weeks of treatment significant decrease of BP levels both in clinic measurements and ABPM was noted regardless of ACE genotype. Losartan dose was titrated in 7 patients with II genotype (70%), 12 patients with ID genotype (48%) and in 4 patients with DD genotype (27%). Patients with DD genotype were characterized by lower systolic and diastolic BP levels after 8 weeks of treatment as compared with carriers of the I allele (ID or II).
Conclusions Our results suggest the association between I/D ACE gene polymorphism and the hypotensive effect of losartan.
Arterial Hypertension 2007, vol. 11, no 6, pages 498-504.

Abstract

Background The insertion/deletion (I/D) ACE gene polymorphism seems the most widely studied sequence variant of human genome. Although evidence implicates the linkage of ACE locus and the risk for arterial hypertension, there are confounding data regarding association of ACE gene polymorphism with blood pressure (BP) response to antihypertensive therapy in patients with essential hypertension.
Therefore the aim of our study was to evaluate the association between I/D ACE polymorphism and antihypertensive efficacy of an angiotensin II receptor blocker - losartan.
Material and methods Fifty patients (mean age 47 ± 8 years) with essential hypertension (stage I-II , ESH/ESC, 2007) were included into the study. The patients were treated with losartan starting from dose of 50 mg once daily. The dose could be increased up to 100 mg once daily if there was no normalization of blood pressure after 4 weeks of treatment. The ambulatory BP measurements (ABPM), clinic BP measurements as well as evaluation of plasma renin activity and serum angiotensin II concentration measurements were performed before and after 8 weeks of treatment. The ACE genotypes were identified by PCR method.
Results The frequency distribution of ACE genotypes were as follows: 20% II homozygotes, 50% ID heterozygotes and 30% DD homozygotes. There were no significant differences in clinic characteristics and baseline BP levels among II, ID or DD patients. After 8 weeks of treatment significant decrease of BP levels both in clinic measurements and ABPM was noted regardless of ACE genotype. Losartan dose was titrated in 7 patients with II genotype (70%), 12 patients with ID genotype (48%) and in 4 patients with DD genotype (27%). Patients with DD genotype were characterized by lower systolic and diastolic BP levels after 8 weeks of treatment as compared with carriers of the I allele (ID or II).
Conclusions Our results suggest the association between I/D ACE gene polymorphism and the hypotensive effect of losartan.
Arterial Hypertension 2007, vol. 11, no 6, pages 498-504.
Get Citation

Keywords

pharmacogenetics; arterial hypertension; losartan; ACE polymorphism

About this article
Title

The I/D ACE gene polymorphism and antihypertensive efficacy of losartan in patients with primary hypertension

Journal

Arterial Hypertension

Issue

Vol 11, No 6 (2007)

Pages

498-504

Published online

2007-10-09

Bibliographic record

Nadciśnienie tętnicze 2007;11(6):498-504.

Keywords

pharmacogenetics
arterial hypertension
losartan
ACE polymorphism

Authors

Magdalena Makowiecka-Cieśla
Andrzej Januszewicz
Grażyna Adler
Agnieszka Bińczak-Kuleta
Iwona Gorący
Mariusz Kaczmarczyk
Jadwiga Janas
Aleksander Prejbisz
Agata Kubaszek
Andrzej Ciechanowicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl